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We reported earlier (S. Singh, N. P. Shanker Narayan, P. J. Jenner, G. Ramu, M. J. Colston, H. K. Prasad,
and I. Nath, Infect. Immun. 62:86-90, 1994) that polyclonal antibodies directed against selective sequences in
the Mycobacterium leprae recombinant protein designated LSR were present in lepromatous leprosy patients
undergoing erythema nodosum leprosum (ENL) reactions (type 2 reactions). In this study using peptides with
single-residue deletions from positions 6 to 24, we define three distinct regions, GVTY, NAA, and RGD, which
were important for antibody recognition and for the discrimination of clinically silent and active ENL
reactions. Antibodies against NAA were found only in patients undergoing active reactions. This is in contrast
to the results for the RGD motif, which was recognized in all ENL patients, irrespective of the clinical status.
Though GVTY was recognized in both groups of patients, its recognition was masked by the flanking glutamic
acid. These findings point towards a specific molecular recognition pattern that emerges when a lepromatous
leprosy patient undergoes immune perturbations leading to ENL reactions. Moreover, the fine specificity of
immunological recognition changes during the natural evolution of the host-parasite interaction.
Lepromatous leprosy (LL), the disseminated multibacillary
form of Mycobacterium leprae infection, is characterized by
specific T-cell unresponsiveness and enhanced B-cell func-
tions. Some patients with LL also suffer from acute, episodic,
reactional states called erythema nodosum leprosum (ENL)
reactions (type 2 reactions), which are characterized by ery-
thematous nodules and systemic manifestations of arthritis and
pyrexia (5, 15). The mechanisms underlying these reactions
have been ascribed variously to polyclonal B-cell activation and
enhanced T-cell reactivity (6, 8). In an attempt to unravel the
target of such immune perturbation, we mapped the B-cell
epitopes of the arginine-rich immunodominant recombinant
fusion protein of M. leprae which we had earlier cloned,
sequenced, and described as LSR (7). Subsequently, the full
gene was found by Sela et al. to code for a 15-kDa protein (12).
We found that patients who were actively undergoing an ENL
reaction had antibodies which recognized two overlapping
peptides, peptide 2, GVTYEIDLTNKNAA (positions 6 to 19),
and peptide 3, IDLTNKNAAKLRGD (positions 11 to 24),
whereas patients who were clinically silent at the time of
sampling had antibodies which recognized only the latter
sequence. We drew attention to the importance of the RGD
motif as a predictor of ENL. In the present study, we provide
evidence for two other B-cell epitopes in peptide 2 which are
the major targets of the antibody response during clinical
activity.
The sera tested were from the individuals previously re-
ported (13). The groups consisted of 44 active reactional
patients (ENL patients) bled prior to the institution of steroid
therapy, 48 lepromatous patients who had a prior history of
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ENL reactions (H/O patients) but showed no clinical activity at
the time of testing, 125 stable lepromatous patients from areas
of endemicity, and 40 healthy volunteers from regions where
leprosy is not endemic (NC group). The patients were diag-
nosed on the basis of Ridley and Jopling classification (10).
Sera reached the laboratory within 24 h of bleeding and were
stored at -20°C.
Sixteen synthetic peptides with single-amino-acid deletions
at either or both termini of the sequence GVTYEIDLT
NKNAAKLRGD, spanning both peptide 2 and peptide 3 of
LSR (peptide 2/3, corresponding to amino acids 6 to 24 [Fig.
1]), were synthesized by a solid-phase methodology (4). An
indirect enzyme-linked immunosorbent assay (ELISA) was
performed as described earlier (13) with peptides at a concen-
tration of 200 ng per well and a 1:125 dilution of sera.
Peroxidase-conjugated rabbit anti-human total immunoglobu-
lin was used as the second antibody, the color was developed
with o-phenylenediamine, and the optical density (OD) was
read at 492 nm. The serum sample was considered positive
when the OD in an ELISA exceeded 3 standard deviations
over the mean value obtained with NC sera. A fluid-phase
competitive ELISA was performed as described above after
prior incubation of sera with various concentrations of the
competing RGD peptide at 37°C for 2 h.
Antibodies against peptide 2/3, which spanned both peptides
2 and 3 (positions 6 to 24), were observed in >86% of
reactional patients, irrespective of disease activity (Fig. 1), and
sera of the ENL and H/O groups showed significant elevation
in OD levels in comparison with sera of stable LL patients (P
< 0.001) (Table 1). The seropositivity to this peptide was
marginally lower than that observed with peptide 2 and peptide
3 used alone (Fig. 1; Table 1).
With peptide 2/3 as the central sequence, peptides incorpo-
rating deletions on either the NH2 or COOH terminus or both
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position
Aminoacid
Sequence
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6-23 GVTYTIDLTNKNAAKLRG
6-22 GVTYEIE DLTNKNAAKLR
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6-19*(p2) GVTYEIDLTNKNAA
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FIG. 1. Percentage of reactional leprosy patients showing seroreactivity to peptides spanning residues 6 to 24 of LSR. Sera from ENL patients(U) and LL H/O patients (1S) were screened at a dilution of 1:125. The asterisks indicate the peptides designated peptide 2 and peptide 3 by Singh
et al. (13). Critical and masking residues are boldfaced and underlined, respectively. Numbers in parentheses represent the number of patients
screened.
termini were used to identify the critical residues in immune
recognition during ENL reactions.
Deletion of residues (G, V, T, and Y) at the NH2 terminus
led to a loss of seroreactivity in both active (ENL) and inactive
(H/I) groups of patients. On deletion of the flanking residue
E (at which point the peptide 3 sequence appears), the
reactivity not only was recovered but also reached maximal
levels both in terms of OD levels (Table 1) and percentage of
reactors (Fig. 1), suggesting that glutamic acid had a negative
effect on binding. Thus, though GVTY was present in peptide
2, its effect was masked by E and it was not recognized by
antibodies of inactive patients until E was deleted.
Sequential deletion of the amino acids in the motif NAA
also led to sequential and selective loss of seroreactivity in
patients with active ENL (Fig. 1). Since peptide 2 contains this
sequence and is recognized only by antibodies of patients
undergoing reactions, NAA would appear to be the critical site
targeted by the antibody response during clinical activity.
Interestingly, algorithms predict significant 1-turn potential (P
> 1.5 x 104) in this region (NKNA) (1, 3, 9).
Deletions at the COOH end of peptide 2/3 further con-
firmed the importance of the RGD motif for antibody recog-
nition (13) in type 2 leprosy reactions (Fig. 1; Table 1), with
both inactive and active reactional patients showing a loss of
seroreactivity with peptides lacking RGD. The importance of
RGD was further strengthened by competitive inhibition as-
says, in which preadsorption with RGD significantly removed
antibody activity against peptides 3 and 2/3 but not peptide 2
(Fig. 2). Interestingly, there were differences in the pattern of
antibody reactivity between the two groups of reactional
patients. Deletion of each residue (R, G, and D) from the
COOH end led to a sequential loss of reactivity in the inactive
reactional patients. In contrast, active ENL sera showed an
O.D AT 492 nm
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FIG. 2. Competitive ELISA with pooled sera from five type 2
(ENL) reactional leprosy patients. Sera were preadsorbed with RGD
and reacted with p2 (GVTYEIDLTNKNAA) (X), p3 (IDLT
NKNAAKLRGD) ([), and p2/3 (GVTYEIDLTNKNAAKLRGD) (*)
in an ELISA. Inhibition was observed only with peptides containing
the RGD sequence (p3 and p2/3).
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TABLE 1. Seroreactivities of multibacillary leprosy patients showing selective recognition of GVTYE, NAA, and RGD motifs in the position
6 to 24 region of LSR2 recombinant protein during reactional states only
Peptide * * Mean OD ± SD for groupb:
.potion Amino acid sequenceapositions ENL (44) LL H/O type 2 (48) Stable LL (125)
11-19 -----IDLTNKNAA----- 0.10 ± 0.01 0.06 ± 0.07 0.05 ± 0.01
11-20 -----IDLTNKNAAK---- <0.01 ± 0.01 0.01 ± 0.03 <0.01 ± 0.05
11-21 -----IDLTNKNAAKL--- 0.02 ± 0.06 0.01 ± 0.03 <0.01 ± 0.01
11-24 -----IDLTNKNAAKLR-D 0.34 ± 0.17 0.14 ± 0.16 0.04 ± 0.06
11-24 (p3)C -----IDLTNKNAAKLRGD 0.50 ± 0.34 0.18 ± 0.14 0.10 ± 0.23
10-24 ----EIDLTNKNAAKLRGD 0.21 ± 0.12 0.06 ± 0.10 0.03 ± 0.01
8-24 --TYEIDLTNKNAAKLRGD 0.29 ± 0.18 0.13 ± 0.12 0.06 ± 0.14
7-24 -VTYEIDLTNKNAAKLRGD 0.35 ± 0.21 0.14 ± 0.11 0.06 ± 0.09
6-24 (p2/3) GVTYEIDLTNKNAAKLRGD 0.41 ± 0.27 0.35 ± 0.18 <0.01 ± 0.07
6-23 GVTYEIDLTNKNAAKLRG- 0.31 ± 0.19 0.20 ± 0.11 0.03 ± 0.01
6-22 GVTYEIDLTNKNAAKLR-- 0.39 ± 0.25 0.10 ± 0.15 0.02 ± 0.05
6-21 GVTYEIDLTNKNAAKL--- 0.19 ± 0.10 0.06 ± 0.04 0.01 ± 0.02
6-20 GVTYEIDLTNKNAAK---- 0.21 ± 0.09 0.03 ± 0.02 0.01 ± 0.02
6-19 (p2)d GVTYEIDLTNKNAA----- 0.34 ± 0.20 0.03 ± 0.02 0.04 ± 0.02
6-18 GVTYEIDLTNKNA------ 0.27 ± 0.15 0.01 ± 0.02 0.01 ± 0.01
6-16 GVTYEIDLTNK-------- 0.09 ± 0.03 0.05 ± 0.04 <0.01 ± 0.01
a Critical and masking residues are boldfaced and underlined, respectively.
b Results are the mean OD ± standard deviation (SD) obtained in an ELISA, with a 1:125 dilution of NC sera having a value of 0.047 + 0.016. Sera showing an
OD of >0.1 (3 SDs above the mean) were considered positive. Numbers in parentheses represent the number of patients tested. Statistical analysis for the test of
significance between responses to peptides within a group was determined by nonparametric analysis (Kruskal-Wallis test [14]).
c Peptide 3 as reported by Singh et al. (13).
d Peptide 2 as reported by Singh et al. (13).
abrupt drop in reactivity only after the deletion of all three
residues (Fig. 1 and Table 1), indicating that the humoral
immune response during clinical activity was discriminatory for
conformational differences in this part of the antigen.
When used alone, RGD showed poor reactivity with active
(11%) and inactive (8%) ENL sera, which may be related to its
small size leading to steric hindrance when absorbed on plastic
plates (2).
In our earlier study, by a method of exclusion we had
concluded that the core sequence of IDLTNKNAA was com-
mon to the peptides recognized by antibodies of both active
and inactive reactional patients (13). When this peptide was
formally tested by ELISA, the reactivity was found to be low
(Fig. 1), thereby confirming that flanking sequences at the NH2
and COOH ends were important for antibody recognition.
Molecular recognition of living organisms may vary during
the course of the natural immune response. In this study, we
show that even over a small stretch of 19 amino acids, multiple
sites are involved in antibody reactivity, and that patients with
different immunopathological manifestations of disease have
different fine specificities. Some sites (NAA) seem important
for evaluating activity, while others, such as RGD, seem
important for predicting a propensity to develop ENL. This
motif is considered the basic recognition unit for adhesion to
fibronectin receptors (11). When these results are considered
in the light of the many potential sites of immunological
recognition in the total organism, of which the 89-amino-acid
LSR forms only a part, one would predict considerably more
immunoreactivity. It is therefore interesting that over 90% of
reactional patients have antibodies predominantly recognizing
these sites. Thus, selectivity seen in the natural human immune
response to intracellular pathogens may provide leads to the
molecular mechanisms which underlie the host-pathogen in-
teraction leading to silent or active disease and could be used
to predict morbidity. Relapses in leprosy can be confused with
mild or silent reactional states, and a diagnostic marker for the
latter would have clinical utility in determining the mode of
treatment.
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